Q3 25 EPS
$0.06
MISS 41.00%
Est. $0.10
Q3 25 Revenue
$599.0M
BEAT +3.30%
Est. $579.8M
vs S&P Since Q3 25
-35.7%
TRAILING MARKET
HIMS -24.4% vs S&P +11.3%
Market Reaction
Did HIMS Beat Earnings? Q3 2025 Results
Hims & Hers Health delivered a split verdict in Q3 2025, posting revenue that topped Wall Street's expectations while earnings fell well short, a combination that nonetheless left investors focused on the company's rapid growth trajectory. Revenue ca… Read more Hims & Hers Health delivered a split verdict in Q3 2025, posting revenue that topped Wall Street's expectations while earnings fell well short, a combination that nonetheless left investors focused on the company's rapid growth trajectory. Revenue came in at $598.98 million, clearing the $579.85 million consensus by 3.30% and representing a 49.2% year-over-year surge, fueled by a 21% jump in subscribers to nearly 2.5 million and a 19% lift in monthly online revenue per subscriber to $80.00. Earnings per share, however, landed at $0.06, missing the $0.10 consensus by 41.00%, as gross margin compressed roughly 500 basis points to 74%, weighed down by shorter shipping cadences in weight loss offerings and higher fulfillment costs. Following the results closely, the board also authorized a $250 million share repurchase program, signaling confidence in the balance sheet. Management narrowed full-year 2025 revenue guidance to $2.33 billion to $2.35 billion, while projecting Q4 revenue of $605 million to $625 million.
Key Takeaways
- • 49% YoY revenue growth driven by 21% subscriber growth and 19% increase in monthly online revenue per average subscriber
- • Subscribers using personalized treatment plans increased 50% YoY
- • Subscribers utilizing treatment plans targeting multiple conditions increased more than 80% YoY, now representing over 20% of total subscribers
- • Marketing efficiency improved with GAAP marketing expense declining from 45% to 39% of revenue
- • Subscriber growth exceeded 40% YoY excluding impact of ongoing transition within on-demand sexual health
- • Adjusted EBITDA grew 53% YoY to $78.4 million
HIMS YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
HIMS Revenue by Segment
With YoY comparisons, source: SEC Filings
HIMS Revenue by Geography
With YoY comparisons, source: SEC Filings
“This quarter we continued to prove that our vision of helping tens of millions of people around the world access best-in-class, personalized care, from the comfort of their own home is more real than ever. We're building a platform that gets more personal, more proactive, and resonates with more people as we scale.”
— Andrew Dudum, Q3 2025 Earnings Press Release
HIMS Earnings Trends
HIMS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
HIMS EPS Trend
Earnings per share: estimate vs actual
HIMS Revenue Trend
Quarterly revenue: estimate vs actual
HIMS Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.03 | $-0.40 | -1,266.18% | $608.1M | -1.42% |
| Q4 25 BEAT FY | $0.04 | $0.08 | +92.31% | $617.8M | +0.09% |
| FY Full Year | $0.47 | $0.51 | +8.46% | $2.35B | +0.03% |
| Q3 25 MISS | $0.10 | $0.06 | -41.00% | $599.0M | +3.30% |
| Q2 25 MISS | $0.23 | $0.17 | -25.83% | $544.8M | -1.31% |
| Q1 25 MISS | $0.23 | $0.20 | -12.32% | $586.0M | +8.84% |
| Q2 22 MISS | $-0.09 | $-0.10 | -11.11% | $113.6M | +9.32% |